Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant for menopausal sleep disturbances
NL-OMON58703Phase 2Completed
- Sponsor
- Bayer Consumer Health
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of elinzanetant in sleep disorder, sponsored by Bayer Consumer Health. Primary endpoint: Change from baseline in wake after sleep onset at Week 4. Started Apr 2024; status: completed.
02
Drugs
elinzanetant
03
Conditions
sleep disorder
Beyond the preview
Go deeper on NL-OMON58703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58703.